The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The prognostic and therapeutic value of EpHA2 in early colorectal cancer (CRC).
Sonali Dasgupta
No relevant relationships to disclose
Sandra Van Schaeybroeck
No relevant relationships to disclose
Philip Dunne
No relevant relationships to disclose
Darragh McArt
No relevant relationships to disclose
Cathy Fenning
No relevant relationships to disclose
Chee Wee Ong
No relevant relationships to disclose
Ken Arthur
No relevant relationships to disclose
Manuel Salto-Tellez
No relevant relationships to disclose
Richard H. Wilson
Consultant or Advisory Role - Hospira; Merck Serono; Roche; Sanofi
Patrick Johnston
No relevant relationships to disclose